|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Han B, Li K, Wang Q, Zhang L, Shi J, Wang
Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a
third-line or further treatment on overall survival of patients
with advanced non-small cell lung cancer: The ALTER 0303 phase 3
randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li
L, Wang F, Hao Y, Li C and Chi Y: Safety, pharmacokinetics, and
antitumor properties of anlotinib, an oral multi-target tyrosine
kinase inhibitor, in patients with advanced refractory solid
tumors. J Hematol Oncol. 9(105)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou
J, Lu Y, Shi Y, Wang Z, Jiang L, et al: Anlotinib as a third-line
therapy in patients with refractory advanced non-small-cell lung
cancer: A multicentre, randomised phase II trial (ALTER0302). Br J
Cancer. 118:654–661. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rami-Porta R, Bolejaek V, Giroux DJ,
Chansky K, Crowley J, Asamura H and Goldstraw P: International
Association for the Study of Lung Cancer Staging and Prognostic
Factors Committee, Advisory Board Members and Participating
Institutions. The IASLC lung cancer staging project: The new
database to inform the eighth edition of the TNM classification of
lung cancer. J Thorac Oncol. 9:1618–1624. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Anderson JL and Morrow DA: Acute
myocardial infarction. N Engl J Med. 376:2053–2064. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Moore RA, Adel N, Riedel E, Bhutani M,
Feldman DR, Tabbara NE, Soff G, Parameswaran R and Hassoun H: High
incidence of thromboembolic events in patients treated with
cisplatin-based chemotherapy: A large retrospective analysis. J
Clin Oncol. 29:3466–3473. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jordan MA and Wilson L: Microtubules as a
target for anticancer drugs. Nat Rev Cancer. 4:253–265.
2004.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Rowinsky EK, McGuire WP, Guarnieri T,
Fisherman JS, Christian MC and Donehower RC: Cardiac disturbances
during the administration of taxol. J Clin Oncol. 9:1704–1712.
1991.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ali RM, Abdul Kader MASK, Wan Ahmad WA,
Ong TK, Liew HB, Omar AF, Zuhdi ASM, Nuruddin AA, Schnorr B and
Scheller B: Treatment of coronary drug-eluting stent restenosis by
a sirolimus- or paclitaxel-coated balloon. JACC Cardiovasc Interv.
12:558–566. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dasanu CA: Gemcitabine: Vascular toxicity
and prothrombotic potential. Expert Opin Drug Saf. 7:703–716.
2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gu L, Zhong D, Yu T, Tang P, Meng F and
Qin Q: Retrospective study of the efficacy and toxicity of
lobaplatin-etoposide chemotherapy in small cell lung cancer. Thorac
Cancer. 10:226–233. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Darby SC, Ewertz M, McGale P, Bennet AM,
Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante
B, et al: Risk of ischemic heart disease in women after
radiotherapy for breast cancer. N Engl J Med. 368:987–998.
2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zamorano JL, Lancellotti P, Rodriguez
Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ,
Lip GYH, Lyon AR, et al: 2016 ESC position paper on cancer
treatments and cardiovascular toxicity developed underthe auspices
of the ESC committee for practice guidelines: The task force for
cancertreatments and cardiovascular toxicity of the European
society of cardiology (ESC). Eur Heart J. 37:2768–2801.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lee CC, Zheng H, Soon YY, Foo LL, Koh WY,
Leong CN, Vellayappan B, Tey JCS and Tham IWK: Association between
radiation heart dosimetric parameters, myocardial infarct and
overall survival in stage 3 non-small cell lung cancer treated with
definitive thoracic radiotherapy. Lung Cancer. 120:54–59.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31.
1995.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676.
2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Baluk P, Hashizume H and McDonald DM:
Cellular abnormalities of blood vessels as targets in cancer. Curr
Opin Genet Dev. 15:102–111. 2005.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Claesson-Welsh L: Blood vessels as targets
in tumor therapy. Ups J Med Sci. 117:178–186. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lugano R, Ramachandran M and Dimberg A:
Tumor angiogenesis: Causes, consequences, challenges and
opportunities. Cell Mol Life Sci. 77:1745–1770. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Abdel-Qadir H, Ethier JL, Lee DS,
Thavendiranathan P and Amir E: Cardiovascular toxicity of
angiogenesis inhibitors in treatment of malignancy: A systematic
review and meta-analysis. Cancer Treat Rev. 53:120–127.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ivy SP, Wick JY and Kaufman BM: An
overview of small-molecule inhibitors of VEGFR signaling. Nat Rev
Clin Oncol. 6:569–579. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Choueiri TK, Schutz FA, Je Y, Rosenberg JE
and Bellmunt J: Risk of arterial thromboembolic events with
sunitinib and sorafenib: A systematic review and meta-analysis of
clinical trials. J Clin Oncol. 28:2280–2285. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dahlberg SE, Sandler AB, Brahmer JR,
Schiller JH and Johnson DH: Clinical course of advanced
non-small-cell lung cancer patients experiencing hypertension
during treatment with bevacizumab in combination with carboplatin
and paclitaxel on ECOG 4599. J Clin Oncol. 28:949–954.
2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Herbst RS, Arkenau HT, Santana-Davila R,
Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG,
Martin-Liberal J, et al: Ramucirumab plus pembrolizumab in patients
with previously treated advanced non-small-cell lung cancer,
gastro-oesophageal cancer, or urothelial carcinomas (JVDF): A
multicohort, non-randomised, open-label, phase 1a/b trial. Lancet
Oncol. 20:1109–1123. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhou M, Chen X, Zhang H, Xia L, Tong X,
Zou L, Hao R, Pan J, Zhao X, Chen D, et al: China national medical
products administration approval summary: Anlotinib for the
treatment of advanced non-small cell lung cancer after two lines of
chemotherapy. Cancer Commun (Lond). 39(36)2019.PubMed/NCBI View Article : Google Scholar
|
